Our Focus on Immuno-Oncology

In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.

The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.

READ MORE

NEWS RELEASE

【Breaking News!】 First MASH treatment approved by FDA

On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res…

READ MORE

EVENT

SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology

We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane…

READ MORE

Cell metab.,

“MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity” (Cell Metab., DOI: 10.1016/j.cmet.2022.10.007., 2022)

READ MORE

STAM™ model

Our STAM™ model is a model that recapitulates the same disease progression as human MASH/HCC.

READ MORE

SERVICE

Search by topics

Our Patented original technologySTAM™ mouse

We are contributing to the world through providing cutting-edge non-clinical pharmacology studies with our unique patented technology, the STAM™ mouse. In order to develop a new drug, it is important to be able to accurately measure the effectiveness of the drug at the non-clinical trial stage. The STAM™ mouse, a model that more accurately reflects human pathology, plays a major role for this purpose.

LEARN MORE

COLUMN

2024.04.08

【Hot data】 Resmetirom (MGL-3196) evaluation data available in STAMTM model

MASHResmetiromSTAM

As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdif…

READ MORE

2024.03.21

What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?

If you are considering a drug evaluation study for liver cancer using a mouse model, our STAMTM-HCC/IO+ model …

READ MORE

2024.03.19

[ Breaking News! ] First MASH treatment approved by FDA

On March 14th, industry-altering news was published. Do you know already what we are talking about? The United…

READ MORE

2024.03.15

[Existing compounds] that have advanced to clinical trials will accelerate the launch of your drugs.

If you are planning to launch your therapeutic drug, you should select disease mouse models that have shown ac…

READ MORE

2024.03.15

Pitfalls of [ disease model mice ] that researchers unknowingly fall into.

In order to evaluate your compound, rather than using a general pulmonary fibrosis model that does not match y…

READ MORE

2024.03.15

| A must for IPF researchers! | Suggestions for the best disease model for your research

If you are considering a drug efficacy study using a mouse model of lung fibrosis, you should use a model that…

READ MORE

VIEW MORE

MODEL LINEUP

Introducing disease mice models related to inflammation, fibrosis, metabolic disorder, cancer, and cancer immunity, including the STAM™ mouse, the world's first MASH model mouse developed in our company.

STAM™ model

DISEASE AREAMASH/NASH-HCCTHERAPEUTIC AREAS

LEARN MORE

Bleomycin-induced pulmonary fibrosis model

DISEASE AREAIPFTHERAPEUTIC AREAS

LEARN MORE

Porcine Pancreatic Elastase (PPE) model

COPDDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

CCl4-induced liver fibrosis model

CirrhosisDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

Bile duct ligation (BDL) model

DISEASE AREAPBCTHERAPEUTIC AREAS

LEARN MORE

TAA-induced acute liver failure model

ALFDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

VIEW MORE

New stage

Our service and disease mouse models bridge the development of the next- Generation Cancer Therapies in the field of Immuno-oncology.

LEARN MORE

New stage

SMC Laboratories,Inc.

COMPANY

At SMC Laboratories, we support drug research with our cutting-edge non-clinical pharmacology studies to quickly deliver therapeutic drugs to patients suffering from diseases that cannot be treated with existing drugs.

LEARN MORE

PUBLICATION

We, SMC Laboratories, are highly regarded worldwide as a consulting – based CRO that designs tailored to the needs of pharmaceutical companies and research institutions.

NEWS

2024.12.09

CytoDyn has published a press release regarding the leronlimab efficacy preclinical study for MASH/fibrosis provided by SMC

CytoDyn Inc., which is our client, has announced the results of pharmacology study using a STAM™ mouse model. …

READ MORE

2024.11.28

Case study: Study published in Clinical and Translational Science on the effects of adiponectin-derived peptide ALY688 in MASH/liver fibrosis of STAM model.

We introduce a case study of pharmacology study of adiponectin-derived peptide ALY688 using our MASH model (ST…

READ MORE

2024.11.15

PUBLICATION

Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~

Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (Nove…

READ MORE

2024.11.05

Case study: Study published in Nature Biotechnology on the effects of TNIK inhibitor in lung and kidney fibrosis models.

We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and af…

READ MORE

2024.10.24

Preclinical HCC study with positive control, Lenvatinib

We recently obtained new evaluation data on the Lenvatinib in our STAM model and it shows significantly improv…

READ MORE

2024.10.17

Enhance Research with Our Updated Model Lineup

We are introducing new disease models to our portfolio of preclinical mouse models. Our extensive lineup offer…

READ MORE

VIEW MORE